RECITALSCollaborative Research, Development and Commercialization Agreement • May 15th, 2001 • Ribozyme Pharmaceuticals Inc • Pharmaceutical preparations
COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Research, Development and Commercialization Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
Each Milestone Payment is due only once and will be payable only upon the first Product to achieve the corresponding Milestone Event for the first time.
COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Research, Development and Commercialization Agreement • November 14th, 2002 • Kosan Biosciences Inc • Services-commercial physical & biological research • Delaware
This Collaborative Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 19th day of September, 2002 (“Effective Date”), by and between:
COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Research, Development and Commercialization Agreement • May 10th, 2006 • Pharmion Corp • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of January 30, 2006 (the “Effective Date”) is made by and between Pharmion Corporation, a corporation organized under the laws of the State of Delaware, USA, with a place of business at 2525-28th Street, Suite 200, Boulder, Colorado, 803301, USA (“Pharmion Corporation”) and Pharmion GmbH, a wholly-owned subsidiary of Pharmion Corporation registered in Switzerland having its principle place of business at Aeschenvorstadt 71, 4051 Basel, Switzerland (“Pharmion GmbH” and, collectively with Pharmion Corporation, “Pharmion”) on the one hand and MethylGene Inc., a corporation organized under the laws of Quebec, Canada, with its principal place of business at 7220 Frederick-Banting, Suite 200, Montreal, Québec H4S 2A1, Canada (“MG”). Each of Pharmion and MG shall be referred to as a “Party” and, together, as the “Parties.”
AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Research, Development and Commercialization Agreement • November 8th, 2004 • Kosan Biosciences Inc • Services-commercial physical & biological research
WHEREAS, Hoffmann-La Roche Inc., a corporation organized and existing under the laws of the State of New Jersey, and F. Hoffmann-La Roche Ltd, a Swiss corporation (collectively, “Roche”), on the one hand, and KOSAN Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (“Kosan”), on the other hand, are parties to that Collaborative Research, Development and Commercialization Agreement entered into as of September 19, 2002 (the “Agreement”); and
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.Collaborative Research, Development and Commercialization Agreement • August 11th, 2021 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
Reference is hereby made to that certain Collaborative Research, Development and Commercialization Agreement (as amended from time to time, the “Agreement”), dated as of June 8, 2018, by and between Revolution Medicines, Inc. (“RevMed”) and Aventis, Inc. (“Aventis”), as amended by that certain letter agreement dated as of August 24, 2018, and as assigned by Aventis to Genzyme Corporation (“Sanofi”) pursuant to that certain Assignment and Assumption Agreement dated as of December 20, 2018. Except as otherwise specifically indicated herein, capitalized terms used but not defined in this letter agreement (this “Letter”) shall have the meanings assigned to them in the Agreement.
